Search bioRxiv⌕ Search

Biology subjects

Markowetz, F.

Publications and source records attributed to Markowetz, F..

At least 19 recordsLinked to original sources

scUnique: Measuring Ongoing Chromosomal Instability

Chromosomal instability is a hallmark of cancer that can drive tumour heterogeneity and treatment resistance. However, scalable methods to measure the dynamics of chromosomal instability are lacking and thus historic genomic scars can be hard to distinguish from markers of currently active mutational processes. Here, we introduce scUnique, a novel approach to measure ongoing chromosomal instability from single-cell whole genome sequencing (scWGS) data. scUnique performs phylogeny-aware joint segmentation to refine single-cell copy number profiles and identifies recent copy number aberrations as statistically supported changes on the leaves of the inferred phylogenetic tree. This yields a per-cell measure of ongoing chromosomal instability at genome-wide resolution. We validate scUnique in (i) a comprehensive benchmarking study, (ii) in CRISPR-Cas-based experimental systems, and (iii) single-cell derived clones of a well-characterised ovarian model. We show that scUnique distinguishes ongoing HRD and FBI mutational processes. These results show that scUnique provides quantitative, scalable, genome-level information about ongoing chromosomal instability, not available in previous studies relying on bulk DNA-sequencing or single-cell imaging. In the future, these improved measurements could refine the understanding of mechanisms of chromosomal instability and lead to dynamic biomarkers for improved treatment decisions.

cancer biology↗

WNT-driven chromosomal instability as a biomarker for PORCN inhibition

Targeting Porcupine (PORCN), a key regulator of the WNT-signalling pathway, has shown therapeutic potential in multiple cancers. Despite strong target engagement and acceptable safety profiles through human phase I clinical trials, low phase II efficacy has stalled further clinical development. Given that aberrant WNT signalling can drive tumorigenesis by inducing chromosomal instability (CIN), we hypothesised that genomic CIN signatures might serve as a predictive biomarker to help improve response rates. Using a controlled in vitro model and single-cell whole-genome sequencing, we demonstrate that acute WNT-activation directly induces three distinct types of CIN: whole genome duplication, replication stress, and impaired homologous recombination. We translated these observations into a composite CIN signature biomarker that significantly correlated with both genetic dependency and pharmacological inhibition of PORCN across 195 and 24 cell lines, respectively. Through a large-scale meta-analysis of patient-derived and cell line xenografts, we established that this composite CIN signature biomarker quantitatively predicts in vivo PORCN inhibitor sensitivity (R=-0.71, p<0.002). By applying an optimised biomarker threshold, refined through modelling of human patient data, to the The Cancer Genome Atlas dataset, we successfully retrospectively modelled previous trial results and identified gastroesophageal cancers as a high-prevalence (36.6%) indication for future development. We validated this strategy in a mouse clinical trial of gastric and esophageal xenografts, where biomarker-guided stratification achieved an objective response rate of 60% and significantly decreased risk of progression (HR=0.21, p=0.0345). These data establish an actionable, trail-ready framework for further PORCN inhibitor clinical development.

cancer biology↗

Deciphering selection patterns of somatic copy-number events

Somatic copy-number alterations (SCNAs) are pervasive across cancers, arising through diverse mutational mechanisms and subsequently shaped by selection according to fitness advantages [1-4]. These alterations can drive tumourigenesis via gene-dosage changes in oncogenes and tumour suppressors [5, 6]. However, observed SCNA profiles do not uniquely define the genomic events that led to them, which is a major obstacle to understanding the selective forces shaping cancer genomes. Here we present SPICE, Selection Patterns In somatic Copy-number Events, an event-level framework that infers discrete copy-number events from allele-specific profiles and models focal selection from first principles, incorporating uniform breakpoint formation and locus-specific selective pressures. Applied to 5,966 samples from the TCGA dataset, SPICE quantifies the full spectrum of SCNA events, recapitulates known mutational processes, and tracks systematic shifts in event types before and after whole-genome duplication (WGD). Next, SPICE employs a generative selection model to identify the location of oncogenes and tumour-suppressors. Unlike previous approaches that detected peaks in aggregated copy-number signals, our model operates directly on inferred events and treats genome-wide breakpoint formation as a neutral reference against which locus-specific selection is detected. This analysis reveals 460 loci under selection which are highly enriched for known oncogenes and tumour suppressors, recapitulating most previously reported sites and uncovering many novel regions, and simultaneously showing that most internal copy-number events are not subject to focal selection. These results establish a unified framework that deconvolves copy-number profiles into their underlying evolutionary events and greatly expand the catalogue of loci implicated in cancer development. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=45 SRC="FIGDIR/small/708809v1_ufig1.gif" ALT="Figure 1"> View larger version (17K): org.highwire.dtl.DTLVardef@7d471corg.highwire.dtl.DTLVardef@c78feeorg.highwire.dtl.DTLVardef@1ba52a8org.highwire.dtl.DTLVardef@188ab0c_HPS_FORMAT_FIGEXP M_FIG C_FIG

cancer biology↗

A Dirichlet-multinomial mixed model for determining differential abundance of mutational signatures

Mutational processes of diverse origin leave their imprints in the genome during tumour evolution. These imprints are called mutational signatures and they have been characterised for point mutations, structural variants and copy number changes. Each signature has an exposure, or abundance, per sample, which indicates how much a process has contributed to the overall genomic change. Mutational processes are not static, and a better understanding of their dynamics is key to characterise tumour evolution and identify cancer weaknesses that can be exploited during treatment. However, the structure of the data typically collected in this context makes it difficult to test whether signature exposures differ between samples or time-points. In general, the data consist of (1) patient-dependent vectors of counts for each sample and clonality group (2) generated from a covariate-dependent and compositional vector of probabilities with (3) a possibly group-dependent over-dispersion level. To model these data, we build on the Dirichlet-multinomial model to be able to model multivariate overdispersed vectors of counts as well as within-sample dependence and positive correlations between signatures. To estimate the model parameters, we implement a maximum likelihood estimator with a Laplace approximation of the random effect high-dimensional integrals and assess its bias and coverage by means of Monte Carlo simulations. We apply our approach to characterise differences of mutational processes between clonal and subclonal mutations across 23 cancer types of the PCAWG cohort. We find ubiquitous differential abundance of clonal and subclonal signatures across cancer types, and higher dispersion of signatures in the subclonal group, indicating higher variability between patients at subclonal level, possibly due to the presence of different clones with distinct active mutational processes. Mutational signature analysis is an expanding field and we envision our framework to be used widely to detect global changes in mutational process activity. Author SummaryThe genome is permanently subject to alterations due to errors in replication, faulty replication machinery, and external mutational processes such as tobacco smoke or UV light. Cancer is a disease of the genome, characterised by an abnormal growth of cells that harbour the same set of "clonal" mutations. In turn, these mutations might transform how cells accrue new "subclonal" mutations or the extent to which they tolerate them. The mutational signature framework lets us extract the information of which mutational processes have been active, and in which intensity, in creating a set of mutations. We extend this framework to statistically test the change in the relative intensity of mutational processes between conditions. In samples of 23 cancer types of the PCAWG project, we test the difference between mutational processes that contribute to mutations prior to cancer onset (clonal group), and upon cancer onset (subclonal group), whilst keeping into consideration patient-to-patient differences. We find differences in the majority of cancer types, and identify mutational processes which contribute preferentially to either group.

cancer biology↗

Pan-cancer evolution signatures link clonal expansion to dynamic changes in the tumour immune microenvironment

Cancer is an evolutionary process characterised by profound intra-tumour heterogeneity. Intra-tumour heterogeneity can be quantified using in silico estimates of cancer cell fractions of tumour-specific somatic mutations. Here we demonstrate a data-driven approach that uses cancer cell fraction distributions to identify 4 robust pan-cancer evolutionary signatures from an analysis of 4,146 individual tumour samples (TCGA) representing 17 distinct cancer types. Evolutionary signatures defined a continuum of cancer cell fractions representing neutral evolution, clonal expansion and fixation. Correlation of evolutionary signatures with programs representing distinct mutational and biological processes demonstrated that individual tumours enriched for clonal expansions and fixations were associated with immune evasion and distinct changes in the tumour immune microenvironment. We observed a dynamic switch between adaptive and innate immune processes as tumours undergo clonal fixation and escape immune surveillance. We also identify mutational processes underpinning different modes of tumour evolution and demonstrate that switching between adaptive and innate immune cell populations is accompanied by the clonal expansion of driver genes that modulate tumour-stroma interactions1.

bioinformatics↗

Predicting response to cytotoxic chemotherapy

Cytotoxic chemotherapies have been a crucial part of cancer treatment for over 40 years. While their primary target is cancer cells, they can also harm normal cells, resulting in dose-limiting toxicity. Most chemotherapies were approved before the advent of precision biomarkers, as such, many patients experience severe toxic side effects without any benefit. To address this challenge, we have developed three precision biomarkers to predict response to platins, taxanes, and anthracyclines. Based on chromosomal instability (CIN) signatures, these biomarkers can be computed from a single genomic test. For platins and taxanes, we used CIN signatures related to impaired homologous recombination, while for anthracyclines, we discovered a CIN signature representing micronuclei induction which predicts resistance. In a clinical study involving 41 high-grade serous ovarian cancers, patients predicted to be sensitive by these biomarkers showed significantly prolonged progression-free survival. To further validate the effectiveness of the taxane and anthracycline predictors, we conducted a retrospective randomised control study involving 182 ovarian and 219 breast cancer patients. Patients predicted as resistant showed increased risk of time to treatment failure compared to standard of care, hazard ratios of 1.73 (95%CI=0.98-3.07) for taxane in ovarian, 3.67 (95%CI=2.12-6.34) for taxane in breast, and 1.93 (95%CI=1.22-3.04) for doxorubicin in ovarian. We also found that liquid biopsies can be used to make these predictions in up to 30% of ovarian cancer patients. Our findings highlight the clinical value of CIN signatures in predicting treatment response to various chemotherapies across multiple different types of cancer. The ability to quantify multiple CIN signature biomarkers using a single genomic test offers a unified approach to guide treatment decisions for cytotoxic chemotherapies. Ultimately, this has the potential to transform the current one-size-fits-all chemotherapy approach into a more precise and tailored form of medicine.

cancer biology↗

scAbsolute: Measuring single-cell ploidy and replication status

Cancer cells often exhibit DNA copy number aberrations and can vary widely in their ploidy. Correct estimation of the ploidy of single cell genomes is paramount for downstream analysis. Based only on single-cell DNA sequencing information, scAbsolute achieves accurate and unbiased measurement of single-cell ploidy and replication status, including whole-genome duplications. We demonstrate scAbsolutes capabilities using experimental cell multiplets, a FUCCI cell cycle expression system, and a benchmark against state-of-the-art methods. scAbsolute provides a robust foundation for single-cell DNA sequencing analysis across different technologies and has the potential to enable improvements in a number of downstream analyses.

genomics↗

High-grade serous ovarian carcinoma organoids as models of chromosomal instability

High-grade serous ovarian carcinoma (HGSOC) is the most genomically complex cancer, characterised by ubiquitous TP53 mutation, profound chromosomal instability and heterogeneity. The mutational processes driving chromosomal instability in HGSOC can be distinguished by specific copy number signatures. To develop clinically relevant models of these mutational processes we derived 15 continuous HGSOC patient-derived organoids (PDOs). We carried out detailed bulk transcriptomic, bulk genomic, single cell genomic, and drug sensitivity characterisation of the organoids. We show that PDOs comprise communities of different clonal populations and represent models of different causes of chromosomal instability including homologous recombination deficiency, chromothripsis, tandem-duplicator phenotype and whole genome duplication. We also show that these PDOs can be used as exploratory tools to study transcriptional effects of copy number alterations as well as compound-sensitivity tests. In summary, HGSOC PDO cultures provide a genomic tool for studies of specific mutational processes and precision therapeutics.

cancer biology↗

Absolute copy number fitting from shallow whole genome sequencing data

Low-coverage or shallow whole genome sequencing (sWGS) approaches can efficiently detect somatic copy number aberrations (SCNAs) at low cost. This is clinically important for many cancers, in particular cancers with severe chromosomal instability (CIN) that frequently lack actionable point mutations and are characterised by poor disease outcome. Absolute copy number (ACN), measured in DNA copies per cancer cell, is required for meaningful comparisons between copy number states, but is challenging to estimate and in practice often requires manual curation. Using a total of 60 cancer cell lines, 148 patient-derived xenograft (PDX) and 142 clinical tissue samples, we evaluate the performance of available tools for obtaining ACN from sWGS. We provide a validated and refined tool called Rascal (relative to absolute copy number scaling) that provides improved fitting algorithms and enables interactive visualisation of copy number profiles. These approaches are highly applicable to both pre-clinical and translational research studies on SCNA-driven cancers and provide more robust ACN fits from sWGS data than currently available tools.

bioinformatics↗

The genomic landscape of early stage ovarian high grade serous carcinoma

PurposeHigh grade serous carcinoma (HGSC) is the commonest type of ovarian cancer. Nearly all HGSC cases are diagnosed at late stage and it is not clear whether early stage HGSC has unique characteristics compared to late stage tumours. Experimental DesignWe analysed samples from 45 patients with FIGO stage I - IIA HGSC - 40 from the pathology archives of three large UK cancer centres and 5 from the BriTROC-1 study. We performed shallow whole genome sequencing (sWGS) and targeted next generation sequencing to investigate somatic mutations and copy number alterations. We compared results to 51 stage IIIC/IV HGSC patients from the BriTROC-1 study. ResultsThere was no difference in median age between the early stage (median 61.3 years, range 40-84) and late stage (median 62.3 years, range 34-76) patients at diagnosis. TP53 mutations were near-universal (92% early stage, 100% late stage samples) and there were no significant differences in the rates of other somatic mutations, including BRCA1 and BRCA2, or focal copy number alterations between early- and late-stage cohorts. There were also no unique amplifications or deletions in either cohort. However, median ploidy was greater in late stage (median 3.1) than early stage (median 2.0) samples. In addition, there were higher numbers of breakpoints per 10MB and per chromosome arm and higher absolute copy number in late stage than early stage cohorts; early stage samples had longer segment length. Overall copy number signature exposures were significantly different between early and late stage samples with greater signature 3 exposure in early stage and greater signature 4 in late stage. Both simplex plot and unsupervised hierarchical clustering suggested that a subset of late stage samples retain early stage appearances with high signature 3 and co-clustering with the early stage samples ConclusionsThese data suggest that there are no unique mutations or focal copy number alterations in early stage HGSC. However, whole genome duplication is significantly more common in late-stage disease, suggesting evolution during disease progression. However, a subset of late stage HGSC retains early-stage features, which are associated with improved overall survival.

cancer biology↗

ZMIZ1 - A novel Estrogen Receptor co-activator that enhances the growth of ER+ breast cancer

The Estrogen Receptor (ER) drives 75% of breast cancers. On activation, the ER recruits co-factors to form a transcriptionally active complex. These co-factors can modulate tumour growth, and understanding their roles can help to identify new therapeutic targets. Here, we present the discovery of an ER-ZMIZ1 interaction by quantitative proteomics, and validated by proximity ligation assay. We characterise ZMIZ1 function by demonstrating that targeting ZMIZ1 results in the reduction of ER transcriptional activity at estrogen response elements and a significant decrease in the proliferation of ER-positive cancer cell lines. To establish a role for the ER-ZMIZ1 interaction, we measured the transcriptional changes in the estrogen response post-ZMIZ1 knockdown using an RNA-seq time-course over 24 hours. GSEA analysis of the ZMIZ1-knockdown data identified a specific delay in the response of estradiol-induced cell-cycle genes. Integration of ENCODE data with our RNA-seq results identified ER and ZMIZ1 binding at the promoter of E2F2. We therefore propose that ER and ZMIZ1 co-regulate an important subset of cell cycle genes via a novel ER-ZMIZ1-E2F2 signalling axis. Finally, we show that high ZMIZ1 expression is predictive of worse patient outcome, ER and ZMIZ1 are co-expressed in breast cancer patients in TCGA, METABRIC, and the proteins are co-localised within the nuclei of tumours cell in patient biopsies. In conclusion, we establish that ZMIZ1 is a regulator of the estrogenic cell cycle response and provide evidence of the biological importance of the ER-ZMIZ1 interaction ER+ patient tumours, supporting potential clinical relevance.

cancer biology↗

3D-printed moulds of renal tumours for image-guided tissue sampling in the clinical setting

PURPOSESpatial heterogeneity of tumours is a major challenge in precision oncology. The relationship between molecular and imaging heterogeneity is still poorly understood, as it relies on the accurate co-registration of medical images and tissue biopsies. tumour moulds can guide the localization of biopsies, but their creation is time consuming, technologically challenging, and difficult to interface with routine clinical practice. These hurdles have so far hindered the progress in the area of multiscale integration of tumour heterogeneity data. METHODSWe have developed an open source computational framework to automatically produce patient-specific 3D-printed moulds that can be used in the clinical setting. Our approach achieves accurate co-registration of sampling location between tissue and imaging, and integrates seamlessly with clinical, imaging and pathology workflows. RESULTSWe applied our framework to patients with renal cancer undergoing radical nephrectomy. We created personalised moulds for five patients, obtaining Dice similarity coefficients between imaging and tissue sections ranging from 0.86 to 0.93 for tumour regions, and between 0.70 and 0.76 for healthy kidney. The framework required minimal manual intervention, producing the final mould design in just minutes, while automatically taking into account clinical considerations such as a preference for specific cutting planes. CONCLUSIONOur work provides a robust and automated interface between imaging and tissue samples, enabling the development of clinical studies to probe tumour heterogeneity on multiple spatial scales.

bioengineering↗

frenchFISH: Poisson models for quantifying DNA copy-number from fluorescence in situ hybridisation of tissue sections

Chromosomal aberration and DNA copy number change are robust hallmarks of cancer. Imaging of spots generated using fluorescence in situ hybridisation (FISH) of locus specific probes is routinely used to detect copy number changes in tumour nuclei. However, it often does not perform well on solid tumour tissue sections, where partially represented or overlapping nuclei are common. To overcome these challenges, we have developed a computational approach called FrenchFISH, which comprises a nuclear volume correction method coupled with two types of Poisson models: either a Poisson model for improved manual spot counting without the need for control probes; or a homogenous Poisson Point Process model for automated spot counting. We benchmarked the performance of FrenchFISH against previous approaches in a controlled simulation scenario and exemplify its use in 12 ovarian cancer FFPE-tissue sections, for which we assess copy number alterations in three loci (c-Myc, hTERC and SE7). We show that FrenchFISH outperforms standard spot counting approaches and that the automated spot counting is significantly faster than manual without loss of performance. FrenchFISH is a general approach that can be used to enhance clinical diagnosis on sections of any tissue.\n\nAuthor summaryCancer genomes can look very chaotic, because cancer cells are unable to fully repair errors in DNA replication during cell division. While a healthy genome has two copies of every chromosome, in a cancer genome some pieces can be lost completely and others can appear in 50 copies. To diagnose cancers and to decide on the right therapeutic strategy for a patient, it can be very important to know how many copies of a particular piece of DNA exist in a cell. The standard technique used in the clinic to assess DNA copy number is called FISH, short for fluorescence in situ hybridisation. This technique uses fluorescent probes that bind to a DNA piece of interest and show up as glowing spots in a microscopic image. Counting the spots in an image is a labour-and time-intensive process that is generally done by well-trained experts. Here we present a statistical approach to automatically count FISH spots, which outperforms previously proposed methods, and has the potential to substantially speed up clinical diagnostics.

bioinformatics↗

Ccube: A fast and robust method for estimating cancer cell fractions

Estimating and clustering cancer cell fractions of genomic alterations are central tasks for studying intratumour heterogeneity. We present Ccube, a probabilistic framework for inferring the cancer cell fraction of somatic point mutations and the subclonal composition from whole-genome sequencing data. We develop a variational inference method for model fitting, which allows us to handle samples with large number of the variants (more than 2 million) while quantifying uncertainty in a Bayesian fashion. Ccube is available at https://github.com/keyuan/ccube.

bioinformatics↗

Genome-wide Estrogen Receptor-alpha activation is sustained, not cyclical

Estrogen Receptor- (ER) is the key driver of 75% of all breast cancers. Upon stimulation by its ligand estra-2-diol, ER forms a transcriptionally active complex binding chromatin. Previous studies have reported that ER binding follows a cyclical binding pattern with a periodicity of 90 minutes. However, these studies have been limited to individual ER target genes and most were done without replicates. Thus, the robustness and generality of ER cycling are not well understood.\n\nHere we present a comprehensive genome-wide analysis of the time dependence of ER binding affinity up to 90 minutes after activation, based on 6 replicates at 10 time points using our previously reported method for precise quantification of binding, Parallel-Factor ChIP-seq (pfChIP-seq). In contrast to previously described cyclical binding, our approach identifies a unidirectional sustained increase in ER binding affinity, as well as a class of estra-2-diol independent binding sites. Our results are corrob-orated by a quantitative re-analysis of data from multiple independent studies.\n\nOur new model reconciles the results of multiple conflicting studies into the activation of ER at the TFF1 promoter. We provide a detailed understanding of ERs response to estra-2-diol in the context of the receptors fundamental role as both the main driver and therapeutic target of breast cancer.

cancer biology↗

Portraits of genetic intra-tumour heterogeneity and subclonal selection across cancer types

Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important clinical challenge. However, the extent, origin and drivers of ITH across cancer types are poorly understood. To address this question, we extensively characterize ITH across whole-genome sequences of 2,658 cancer samples, spanning 38 cancer types. Nearly all informative samples (95.1%) contain evidence of distinct subclonal expansions, with frequent branching relationships between subclones. We observe positive selection of subclonal driver mutations across most cancer types, and identify cancer type specific subclonal patterns of driver gene mutations, fusions, structural variants and copy-number alterations, as well as dynamic changes in mutational processes between subclonal expansions. Our results underline the importance of ITH and its drivers in tumor evolution, and provide an unprecedented pan-cancer resource of comprehensively annotated subclonal events from whole-genome sequencing data.

cancer biology↗

Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors

Targeted therapy for patients with HER2 positive (HER2+) breast cancer has improved the overall survival, but many patients still suffer relapse and death of the disease. Intra-tumor heterogeneity of both estrogen receptor (ER) and HER2 expression has been proposed to play a key role in treatment failure, but little work has been done to comprehensively study this heterogeneity at the single-cell level.\n\nIn this study, we explored the clinical impact of intra-tumor heterogeneity of ER protein expression, HER2 protein expression, and HER2 gene copy number alterations. Using combined immunofluorescence and in situ hybridization on tissue sections followed by a validated computational approach, we analyzed more than 13,000 single tumor cells across 37 HER2+ breast tumors. The samples were taken both before and after neoadjuvant chemotherapy plus HER2-targeted treatment, enabling us to study tumor evolution as well.\n\nWe found that intra-tumor heterogeneity for HER2 copy number varied substantially between patient samples. Highly heterogeneous tumors were associated with significantly shorter disease-free survival and fewer long-term survivors. Patients for which HER2 characteristics did not change during treatment had a significantly worse outcome.\n\nThis work shows the impact of intra-tumor heterogeneity in molecular diagnostics for treatment selection in HER2+ breast cancer patients and the power of computational scoring methods to evaluate in situ molecular markers in tissue biopsies.

cancer biology↗

Network Dynamics of ER-α activation reveals reprogramming of GRHL2

VULCAN infers regulatory interactions of transcription factors by overlaying networks generated from tumor expression data onto ChIP-seq data. VULCAN analysis of estrogen receptor (ER) activation in breast cancer highlighted key components of the ER complex alongside a novel interaction with GRHL2. We demonstrate that GRHL2 is recruited to a subset of ER binding sites and regulates the transcriptional output of ER, as evidenced by: changes in ER-associated eRNA expression; and stronger ER binding at active enhancers (H3K27ac sites) after GRHL2 knockdown. Our findings provide new insight into ER signaling and demonstrate VULCAN, available from Bioconductor, as a powerful predictive tool.

cancer biology↗